Clinical trials: Liver Diseases, Alcoholic
Fatty Liver, Nonalcoholic, Meal Time
Hepatic Glycogen and Fat Oxidation
Excessive fat in the liver is associated with impairments in metabolic health. Low levels of DNL and high levels of hepatic fat oxidation are considered to be protective.
- Conditions
- Fatty Liver, Nonalcoholic, Meal Time, Fasting, Glycogen Depletion
- Trial name
- NCT03593343
- Testing
- Overnight fasting duration
- Where
- Netherlands
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Nonalcoholic Fatty Liver
Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) Study 1.2
This study is a prospective, observational, single-center, short-term cross-sectional study to assess the repeatability and reproducibility of a set of specified MRI quantitative biomarkers.
- Trial name
- NCT05081427
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Fatty Liver
Metformin in Non-Alcoholic Fatty Liver Disease
The study evaluates the use of the antidiabetic medicine metformin in nonalcoholic fatty liver disease.
- Trial name
- NCT00303537
- Testing
- metformin
- Where
- 4 sites in Norway
- Volunteers
- 90 people
- Sponsor
- University Hospital, Aker
Non-alcoholic Steatohepatitis
Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis
Patients with non-alcoholic fatty liver disease (NAFLD) are at increased risk of more aggressive liver disease; non-alcoholic steatohepatitis (NASH) and at a higher risk of death from cirrhosis, hepatocellular carcinoma and…
- Trial name
- NCT05254626
- Testing
- Dapagliflozin 10Mg Tab, Pioglitazone 30 mg
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Non-Alcoholic Fatty Liver Disease
Efficacy of Phosphatidylcholine in NAFLD
This study evaluates efficacy of Phosphatidylcholine in addition to life style modification and patient health education by clinical Pharmacist in the Management of Non Alcoholic Fatty Liver NAFLD.
- Trial name
- NCT04411862
- Testing
- Phosphatidyl Choline, Lifestyle modification
- Volunteers
- 100 people
- Sponsor
- Nehal Abou Seada
Non-alcoholic Fatty Liver Disease, Obesity
Metabolic Flexibility, Gut Microbiota, Healthy Diet and Exercise in NAFLD on Genetics Base
Nonalcoholic fatty liver disease (NAFLD) is associated to obesity, metabolic syndrome and genetic predisposition: specific variants of the genes PNPLA3 and TM6SF2 are the most involved.
- Trial name
- NCT02951546
- Testing
- Mediterranean diet, Low fat diet, Aerobic exercise
- Where
- Italy
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes
Weight Gain After Smoking Cessation and NAFLD
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common chronic liver disease. Considering that there are no approved pharmacological treatments, lifestyle modification is necessary and challenging to reduce…
- Trial name
- NCT05550688
- Where
- China
- Volunteers
- 12,941 people, healthy volunteers welcome
- Sponsor
- Ningbo No. 1 Hospital
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Soluble Fibre Supplementation in NAFLD
The FIND study will look at the effect of a nutritional mixed fibre supplement, oligofructose and inulin (OF+INU), on children with non-alcoholic fatty liver disease.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Hepatic Steatosis
- Trial name
- FIND (NCT05480696)
- Testing
- Fructo-oligosaccharide enriched inulin supplement, Maltodextrin
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- McMaster University
NAFLD, Insulin Resistance
Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian
Getting a rough indicator about the prevalence of different grade of severity of NAFLD (NASH \& liver fibrosis), and Correlate the severity of fatty liver with different serological risk factors of metabolic syndrome and diseases…
- Conditions
- NAFLD, Insulin Resistance, Hepatic Steatosis
- Trial name
- NCT04081571
- Where
- Egypt
- Volunteers
- 1,080 people
- Sponsor
- Cairo University
NAFLD, ACS - Acute Coronary Syndrome
Prevalence of NAFLD in ACS Patients
Addressing CVD risk in patients with NAFLD is the aspect of the disease most amenable to medical management and so improving long-term clinical outcomes.
- Trial name
- PADAC (NCT05378321)
- Testing
- Non-invasive diagnostic testing
- Where
- Belgium
- Volunteers
- 225 people
- Sponsor
- Ziekenhuis Oost-Limburg
Lipodystrophy
Leptin to Treat Lipodystrophy
This study will evaluate the safety and effectiveness of the leptin replacement therapy in treating lipoatrophy or lipodystrophy-a condition in which there is a total or partial loss of fat cells.
- Trial name
- NCT00005905
- Testing
- hu Leptin (A-100)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-alcoholic Fatty Liver Disease
Effects of Aerobic Exercise on Lean Non-alcoholic Fatty Liver Disease (NAFLD)
NAFLD is increasingly being identified in lean individuals, especially in Chinese population. Among the NAFLD patients, the lean NAFLD accounts for 15.9%-23.0%.
- Trial name
- NCT04882644
- Testing
- Aerobic Exercise
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non-alcoholic Fatty Liver Disease
A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)
The objective of this study is to demonstrate a reduction of intrahepatic fat as measured with Proton Magnetic Resonance Spectroscopy after 12 weeks administration of oral acarbose.
- Trial name
- NCT00677521
- Testing
- Acarbose
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- The Hospital for Sick Children
Atherosclerosis, Non-alcoholic Fatty Liver Disease
Correlation Between NAFLD, Epicardial Adipose Tissue and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)
Vascular inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular…
- Trial name
- NCT01958411
- Where
- South Korea
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Korea University
NAFLD
Serum Selenium and Zinc Levels in Non-alcoholic Fatty Liver Disease Patients
Non-alcoholic fatty liver disease (NAFLD) includes a wide range of disorders that consist of simple fatty infiltration, steatohepatitis (NASH), and end-stage liver disease (cirrhosis).
- Trial name
- NAFLD (NCT04834063)
- Testing
- Serum Zinc a level, serum selenium level, Fibroscan measurement
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sohag University
Nonalcoholic Fatty Liver Disease, Hepatic Steatosis
A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection
The purpose of this study is to measure the effect of a short-term low calorie diet on patients with a Body Mass Index (BMI) over 25 who are undergoing liver surgery.
- Conditions
- Nonalcoholic Fatty Liver Disease, Hepatic Steatosis, Steatohepatitis
- Trial name
- NCT01645852
- Testing
- Optifast 800
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT04501406
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- University of Florida
Non-Alcoholic Fatty Liver Disease
Characterization and Technical Evaluation of cT1 for NASH (CATE-NASH)
The primary objective of this study is to evaluate to provide evidence to establish tightly defined cut-offs to identify patients for NASH clinical trial inclusion using cT1 and/or PDFF.
- Trial name
- NCT04341246
- Testing
- LiverMultiscan
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Perspectum
Non-alcoholic Fatty Liver Disease
Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
The study is designed to assess the safety and efficacy of different doses and dosing regimens of Runihol, tablets, enteric coated, produced by "NTFF" POLYSAN" (Russia), in prevention of liver disease progression in patients with…
- Trial name
- NCT02930161
- Testing
- Runihol
- Where
- 3 sites in Russia
- Volunteers
- 35 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
HIV/AIDS, Alcoholic Hepatitis
Immunology of HIV and Alcoholic Hepatitis
This is prospective, longitudinal cohort study involving HIV-positive, antiretroviral (ART)-treated, heavy alcohol drinking participants who have and do not have alcoholic hepatitis.
- Trial name
- NCT03951662
- Testing
- Alcoholic Hepatitis Group, Heavy Drinking Controls without Hepatitis
- Where
- United States
- Sponsor
- Indiana University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.